177 related articles for article (PubMed ID: 35593350)
1. Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy.
Mitra R; Ayyannan SR
Anticancer Agents Med Chem; 2022; 22(18):3062-3085. PubMed ID: 35593350
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
3. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
4. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H
Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles.
Stitzlein LM; Gangadharan A; Walsh LM; Nam D; Espejo AB; Singh MM; Patel KH; Lu Y; Su X; Ezhilarasan R; Gumin J; Singh S; Sulman E; Lang FF; Chandra J
Front Neurol; 2023; 14():1112207. PubMed ID: 37082446
[TBL] [Abstract][Full Text] [Related]
6. Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases.
Mao F; Shi YG
Adv Exp Med Biol; 2023; 1433():15-49. PubMed ID: 37751134
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
8. LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response.
Faletti S; Osti D; Ceccacci E; Richichi C; Costanza B; Nicosia L; Noberini R; Marotta G; Furia L; Faretta MR; Brambillasca S; Quarto M; Bertero L; Boldorini R; Pollo B; Gandini S; Cora D; Minucci S; Mercurio C; Varasi M; Bonaldi T; Pelicci G
Sci Transl Med; 2021 Dec; 13(623):eabf7036. PubMed ID: 34878824
[TBL] [Abstract][Full Text] [Related]
9. Lysine Demethylation in Pathogenesis.
Cao J; Yan Q
Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133
[TBL] [Abstract][Full Text] [Related]
10. A novel mammalian flavin-dependent histone demethylase.
Karytinos A; Forneris F; Profumo A; Ciossani G; Battaglioli E; Binda C; Mattevi A
J Biol Chem; 2009 Jun; 284(26):17775-82. PubMed ID: 19407342
[TBL] [Abstract][Full Text] [Related]
11. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase.
Laurent B; Shi Y
Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
13. Crystal Structure of the LSD1/CoREST Histone Demethylase Bound to Its Nucleosome Substrate.
Kim SA; Zhu J; Yennawar N; Eek P; Tan S
Mol Cell; 2020 Jun; 78(5):903-914.e4. PubMed ID: 32396821
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance.
Agboyibor C; Dong J; Effah CY; Drokow EK; Ampomah-Wireko M; Pervaiz W; Sangmor A; Ma X; Li J; Liu HM; Zhang P
Biomed Pharmacother; 2023 Jan; 157():113934. PubMed ID: 36395607
[TBL] [Abstract][Full Text] [Related]
15. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1α-dependent pathway.
Saccà CD; Gorini F; Ambrosio S; Amente S; Faicchia D; Matarese G; Lania L; Majello B
Biochim Biophys Acta Gene Regul Mech; 2019 May; 1862(5):535-546. PubMed ID: 30951900
[TBL] [Abstract][Full Text] [Related]
17. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
18. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process.
Forneris F; Binda C; Vanoni MA; Mattevi A; Battaglioli E
FEBS Lett; 2005 Apr; 579(10):2203-7. PubMed ID: 15811342
[TBL] [Abstract][Full Text] [Related]
19. LSD1: more than demethylation of histone lysine residues.
Perillo B; Tramontano A; Pezone A; Migliaccio A
Exp Mol Med; 2020 Dec; 52(12):1936-1947. PubMed ID: 33318631
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells.
Hino S; Kohrogi K; Nakao M
Cancer Sci; 2016 Sep; 107(9):1187-92. PubMed ID: 27375009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
